We’re happy to announce that we have entered into a research and sales agreement with American Leprosy Missions! This partnership enables ALM to adapt our mobile molecular point-of-need testing technology to serve those affected by, or at risk of, neglected tropical diseases (NTDs) and other infectious diseases like COVID-19.
ALM and its network of research partners plan to develop rapid, reliable molecular diagnostic solutions for use in remote contexts. At the heart of the solution is our mobile qPCR thermocycler, Franklin™, and our field-ready, shelf-stable reagents, reducing their time-to-results from an average of 6 to 9 months down to less than an hour.
American Leprosy Missions, based in Greenville, South Carolina, is dedicated to curing and caring for people affected by leprosy and other neglected tropical diseases. It supports projects, research and partners in countries across Africa, Asia and the Americas. Since its founding in 1906, American Leprosy Missions has provided holistic care to more than four million people around the world including medical treatment and training, community development, vaccine research and innovative ventures like the AIM Initiative.
We couldn’t be more excited to collaborate with ALM’s team of scientists and practitioners who are clearly committed to serving those affected by NTDs and those impacted by the COVID-19 pandemic.
Check out the full press release over at the American Leprosy Missions website to learn more!
